nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

10.10.2019 | Original Article – Clinical Oncology

Microwave ablation as local consolidative therapy for patients with extracranial oligometastatic EGFR-mutant non-small cell lung cancer without progression after first-line EGFR-TKIs treatment

verfasst von: Yang Ni, Xin Ye, Xia Yang, Guanghui Huang, Wenhong Li, Jiao Wang, Xiaoying Han, Zhigang Wei, Min Meng

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Evidence from multiple clinical trials showed that local consolidative therapy (LCT) improved survival in oligometastatic non-small cell lung cancer (NSCLC) patients. In the present study, we aim to explore the potential role of microwave ablation (MWA) as LCT for epidermal growth factor receptor (EGFR)-mutant advanced NSCLC patients with extracranial oligometastasis.

Materials and methods

From January 2015 to December 2018, a total of 86 EGFR-mutant stage IIIB or IV NSCLC patients with extracranial oligometastasis were enrolled for retrospective analysis. MWA was used as LCT for all oligometastatic lesions and/or primary tumors in 34 patients without progression after first-line EGFR-TKIs therapy (consolidation group), while the other 52 patients received only TKIs until disease progression (monotherapy group). We calculated and compared the progression-free survival (PFS) and overall survival (OS) of the two groups.

Results and conclusion

Patients with MWA consolidation therapy had significantly improved PFS (median 16.7 vs. 12.9 months, HR 0.44, 95% CI 0.22–0.88, P = 0.02) and OS (median: 34.8 vs. 22.7 months, HR 0.45, 95% CI 0.24–0.88, P = 0.04) than monotherapy group. MWA for LCT was identified as the independent predictive factor for better PFS (HR 0.46, 95% CI 0.37–0.82, P < 0.01) and OS (HR 0.57, 95% CI 0.33–0.91, P = 0.02). Most toxicities were mild and well tolerated. No patient had to discontinue EGFR-TKIs because of MWA complications. These findings suggest that MWA as local consolidative therapy after first-line EGFR-TKIs treatment leads to better disease control and survival than TKIs monotherapy in EGFR-mutant advanced NSCLC patients with extracranial oligometastasis. MWA as a novel option of LCT might be considered for clinical management of these patients.

de Baere T, Tselikas L, Catena V, Buy X, Deschamps F, Palussiere J (2016) Percutaneous thermal ablation of primary lung cancer. Diagn Interv Imaging. 97(10):1019–1024CrossRef

Gomez DR, Blumenschein GR Jr, Lee JJ, Hernandez M, Ye R, Camidge DR et al (2016) Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 17(12):1672–1682CrossRef

Gomez DR, Tang C, Zhang J, Blumenschein GR Jr, Hernandez M, Lee JJ et al (2019) Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol. 8:JCO1900201

Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13(1):8–10CrossRef

Inal A, Kodaz H, Odabas H, Duran AO, Seker MM, Inanc M et al (2018) Prognostic factors of patients who received chemotherapy after cranial irradiation for non-small cell lung cancer with brain metastases: a retrospective analysis of multicenter study (Anatolian Society of Medical Oncology). J Cancer Res Ther. 14(3):578–582CrossRef

Jiang T, Chu Q, Wang H, Zhou F, Gao G, Chen X et al (2019) EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases. Int J Cancer 144(10):2605–2612CrossRef

Juan O, Popat S (2017) Ablative therapy for oligometastatic non-small cell lung cancer. Clin Lung Cancer. 18(6):595–606CrossRef

Khan AJ, Mehta PS, Zusag TW, Bonomi PD, Penfield Faber L, Shott S et al (2006) Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC). Radiother Oncol 81(2):163–167CrossRef

Kim C, Hoang CD, Kesarwala AH, Schrump DS, Guha U, Rajan A (2017) Role of local ablative therapy in patients with oligometastatic and oligoprogressive non-small cell lung cancer. J Thorac Oncol. 12(2):179–193CrossRef

Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 11(2):121–128CrossRef

Ni Y, Bi J, Ye X, Fan W, Yu G, Yang X et al (2016) Local microwave ablation with continued EGFR tyrosine kinase inhibitor as a treatment strategy in advanced non-small cell lung cancers that developed extra-central nervous system oligoprogressive disease during EGFR tyrosine kinase inhibitor treatment: a pilot study. Medicine (Baltimore). 95(25):e3998CrossRef

Ni Y, Liu B, Ye X, Fan W, Bi J, Yang X et al (2019) Local thermal ablation with continuous EGFR tyrosine kinase inhibitors for EGFR-mutant non-small cell lung cancers that developed extra-central nervous system (CNS) oligoprogressive disease. Cardiovasc Intervent Radiol 42(5):693–699CrossRef

Parikh RB, Cronin AM, Kozono DE, Oxnard GR, Mak RH, Jackman DM et al (2014) Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer. Int J Radiat Oncol Biol Phys 89(4):880–887CrossRef

Pusceddu C, Melis L, Sotgia B, Guerzoni D, Porcu A, Fancellu A (2019) Usefulness of percutaneous microwave ablation for large non-small cell lung cancer: a preliminary report. Oncol Lett. 18(1):659–666PubMedPubMedCentral

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13(3):239–246CrossRef

Solbiati LA (2018) A valuable guideline for thermal ablation of primary and metastatic lung tumors. J Cancer Res Ther 14(4):725–726CrossRef

Song Z, Qi H, Zhang H, Xie L, Cao F, Fan W et al (2017) Microwave ablation: results with three different diameters of antennas in ex vivo bovine and in vivo porcine liver. J Cancer Res Ther 13(5):737–741CrossRef

Soria JC, Wu YL, Nakagawa K, Kim SW, Yang JJ, Ahn MJ et al (2015) Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol. 16(8):990–998CrossRef

Vogl TJ, Nour-Eldin NA, Albrecht MH, Kaltenbach B, Hohenforst-Schmidt W, Lin H et al (2017a) Thermal ablation of lung tumors: focus on microwave ablation. Rofo. 189(9):828–843CrossRef

Vogl TJ, Nour-Eldin NA, Hammerstingl RM, Panahi B, Naguib NNN (2017b) Microwave ablation (MWA): basics, technique and results in primary and metastatic liver neoplasms—review article. Rofo. 189(11):1055–1066CrossRef

Wei Z, Ye X, Yang X, Zheng A, Huang G, Li W et al (2017) Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations. Oncotarget. 8(34):56714–56725PubMedPubMedCentral

Weichselbaum RR, Hellman S (2011) Oligometastases revisited. Nat Rev Clin Oncol. 8(6):378–382CrossRef

Xu Q, Zhou F, Liu H, Jiang T, Li X, Xu Y et al (2018) Consolidative local ablative therapy improves the survival of patients with synchronous oligometastatic NSCLC harboring EGFR activating mutation treated with first-line EGFR-TKIs. J Thorac Oncol. 13(9):1383–1392CrossRef

Yang X, Ye X, Zheng A, Huang G, Ni X, Wang J et al (2014) Percutaneous microwave ablation of stage I medically inoperable non-small cell lung cancer: clinical evaluation of 47 cases. J Surg Oncol 110(6):758–763CrossRef

Yang X, Ye X, Huang G, Han X, Wang J, Li W et al (2017) Repeated percutaneous microwave ablation for local recurrence of inoperable stage I nonsmall cell lung cancer. J Cancer Res Ther. 13(4):683–688CrossRef

Yang X, Ye X, Lin Z, Jin Y, Zhang K, Dong Y et al (2018) Computed tomography-guided percutaneous microwave ablation for treatment of peripheral ground-glass opacity-lung adenocarcinoma: a pilot study. J Cancer Res Ther. 14(4):764–771CrossRef

Ye X, Fan W, Wang H, Wang J, Wang Z, Gu S et al (2018) Expert consensus workshop report: guidelines for thermal ablation of primary and metastatic lung tumors (2018 edition). J Cancer Res Ther. 14(4):730–744CrossRef

Titel: Microwave ablation as local consolidative therapy for patients with extracranial oligometastatic EGFR-mutant non-small cell lung cancer without progression after first-line EGFR-TKIs treatment
verfasst von: Yang Ni
Xin Ye
Xia Yang
Guanghui Huang
Wenhong Li
Jiao Wang
Xiaoying Han
Zhigang Wei
Min Meng
Publikationsdatum: 10.10.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 1/2020
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-019-03043-6

Springer Medizin

Microwave ablation as local consolidative therapy for patients with extracranial oligometastatic EGFR-mutant non-small cell lung cancer without progression after first-line EGFR-TKIs treatment